Details for New Drug Application (NDA): 050627
NDA 050627 describes RIFADIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. Additional details are available on the RIFADIN profile page.
The generic ingredient in RIFADIN is rifampin. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
The generic ingredient in RIFADIN is rifampin. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
Summary for 050627
| Tradename: | RIFADIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | rifampin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 050627
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 600MG/VIAL | ||||
| Approval Date: | May 25, 1989 | TE: | AP | RLD: | Yes | ||||
Complete Access Available with Subscription
